Trasylol (aprotinin) as an anti-tumour agent.
Growth of a syngeneic adenocarcinoma in C3H mice was investigated in animals receiving twice-daily subcutaneous injections of the antiprotease Trasylol. Development of primary tumours was not influenced by Trasylol treatment and the antiprotease did not affect concomitant ant--tumour immunity as assessed by resistance to secondary footpad challenge. From histological examination of tumours and a study of GVH (graft-versus-host) activity no evidence was gained that Trasylol treatment augments the host cellular immune response.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D000818:Animals; D007611:Aprotinin / Q000627:therapeutic use*; D005260:Female; D007111:Immunity, Cellular / Q000187:drug effects*; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D007611:Aprotinin